fincash logo SOLUTIONS
EXPLORE FUNDS
CALCULATORS
LOG IN
SIGN UP

Fincash » Search » Marksans Pharma Ltd

Marksans Pharma Ltd

Updated on August 9, 2020

Stock/Share Code - MARKSANS

Marksans Pharma is engaged in Business of Formulation of pharmaceutical products.

Below is the details of MARKSANS Marksans Pharma Ltd

Market Cap₹929.14 Cr.
Current Price ₹48.95 as on 14 Aug 20
52 Week High / Low Price₹23.8 / ₹9.85
Face Value₹1
Stock P/E25.72
Book Value₹11.85
Dividend Yield0.22 %
ROCE11.99 %
ROE9.70 %
Sales Growth (3yrs)5.80 %
SectorPharmaceuticals
IndustryPharmaceuticals - Indian - Bulk Drugs
Listed onBSE  AND  NSE
Company WebsiteCompany Website
Pros: Company is virtually debt free.
Cons: The company has delivered a poor growth of 6.14% over past five years. Company has a low return on equity of 5.22% for last 3 years. Earnings include an other income of Rs.19.53 Cr. Dividend payout has been low at 12.96% of profits over last 3 years Company has high debtors of 153.03 days.

Marksans Pharma Ltd Price Chart

Marksans Pharma Ltd Price Chart

Marksans Pharma Ltd Peer Comparison in Pharmaceuticals

S.No. Name CMP Rs. P/E Mar Cap Rs.Cr. Div Yld % NP Qtr Rs.Cr. Qtr Profit Var % Qtr Sales Var % Sales Qtr Rs.Cr. ROCE %
1. Divi's Lab. ₹141.4 49.56 ₹63,449.65 Cr. 0.67 ₹359.09 Cr. -7.78 2.67 1396.26 28.51
2. Lupin ₹1,018.2 ₹39,407.16 Cr. 0.57 ₹389.63 Cr. 12.32 -1.05 3845.74 9.97
3. Jubilant Life ₹807.75 7.64 ₹7,043.45 Cr. 1.13 ₹260.49 Cr. 248.25 0.24 2391.41 16.37
4. Granules India ₹306.9 13.30 ₹4,353.99 Cr. 0.58 ₹64.03 Cr. 39.82 11.42 703.96 14.75
5. Shilpa Medicare ₹622.5 21.97 ₹3,203.19 Cr. 0.28 ₹55.06 Cr. 248.70 36.57 236.85 8.74
6. Aarti Drugs ₹2,115.4 17.47 ₹2,265.34 Cr. 0.21 ₹56.56 Cr. 118.69 -6.00 406.57 17.00
7. Sequent Scien. ₹132.65 30.12 ₹2,106.19 Cr. 0.24 ₹16.86 Cr. -1.52 6.72 300.83 9.21
8. Marksans Pharma 25.72 ₹929.14 Cr. 0.22 ₹12.98 Cr. 10.19 -6.64 116.88 11.99

Ready to Invest?
Talk to our investment specialist
Disclaimer:
By submitting this form I authorize Fincash.com to call/SMS/email me about its products and I accept the terms of Privacy Policy and Terms & Conditions.

Marksans Pharma Ltd Fundamentals

Quarterly Results

Quarterly reports are issued by companies every three months. Most companies have a financial year-end of Mar. 31 and quarters that end on June 30, Sept. 30, Dec. 31 and March 31.

Standalone Figures in Rs. Crores

Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019
Sales -5452758087931151259192101117
YOY Sales Growth %-22.30%25.36%35.82%23.92%60.96%77.78%52.04%56.43%5.00%-0.77%-12.15%-6.64%
Expenses -5345696976769710888828897
Material Cost %53%52%62%58%56%50%55%59%58%60%62%55%
Employee Cost %19%23%15%15%13%12%10%10%12%13%12%11%
Operating Profit18612111718173101320
OPM %1%15%8%14%12%18%16%14%4%11%13%17%
Other Income0000033010280
Interest212132212221
Depreciation443332222333
Profit before tax-53186171714981616
Tax %51%58%-138%27%24%17%25%16%36%28%24%19%
Net Profit-21164141212661213
EPS in Rs-0.060.030.030.140.110.340.300.290.140.140.290.32
NotesNotesNotesNotesNotesNotesNotesNotesNotesNotesNotesNotes

Profit & Loss

The profit and loss (P&L) statement is a financial statement that summarizes the revenues, costs and expenses incurred during a specified period, usually a fiscal quarter or year. The P&L statement is synonymous with the income statement. These records provide information about a company's ability or inability to generate profit" by increasing revenue, reducing costs or both. Some refer to the P&L statement as a statement of profit and loss, income statement, statement of operations, statement of financial results or income, earnings statement or expense statement.

Standalone Figures in Rs. Crores

Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019TTM
Sales -236200200155155192315406358216295424401
Sales Growth %2.98%-15.62%0.02%-22.48%-0.07%24.39%63.78%28.78%-11.70%-39.73%36.52%43.95%
Expenses -208179176235272148231290254191266361354
Material Cost %68%67%73%69%57%53%54%54%50%52%57%56%
Manufacturing Cost %5%5%4%4%7%8%5%4%5%7%5%4%
Employee Cost %6%6%5%7%9%8%7%6%7%18%16%11%
Other Cost %9%12%6%71%104%8%8%8%9%12%12%14%
Operating Profit292024-81-118448411610424296347
OPM %12%10%12%-52%-76%23%27%29%29%11%10%15%12%
Other Income1071-792433977820
Interest111515394910151364877
Depreciation910101518999151512910
Profit before tax1921-213-1833063979212175648
Tax %23%79%54%-2%1%-34%12%31%22%3%25%22%
Net Profit1500-218-1814056677112124436
EPS in Rs0.041.031.421.611.720.190.301.070.89
Dividend Payout %0%0%0%-0%-0%0%7%7%7%18%16%5%

Compounded Sales Growth

  • 10 Years:: 7.83%
  • 5 Years:: 6.14%
  • 3 Years:: 5.80%
  • TTM:: -4.44%

Compounded Profit Growth

  • 10 Years:: 54.32%
  • 5 Years:: -4.71%
  • 3 Years:: -15.16%
  • TTM:: -14.65%

Return on Equity

  • 10 Years:: 18.38%
  • 5 Years:: -17.23%
  • 3 Years:: -20.54%
  • 1 Year:: -0.44%

Balance Sheet

A balance sheet is a financial statement that reports a company's assets, liabilities and shareholders' equity at a specific point in time, and provides a basis for computing rates of return and evaluating its capital structure. It is a financial statement that provides a snapshot of what a company owns and owes, as well as the amount invested by shareholders. It is used alongside other important financial statements such as the income statement and statement of cash flows in conducting fundamental analysis or calculating financial ratios.

Standalone Figures in Rs. Crores

Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Sep 2019
Share Capital -49505050505252535341414141
Preference Capital13.5013.5013.5013.5013.5013.5013.5012.5012.500.000.000.00
Equity Capital35.9436.7836.7836.7836.7838.5338.5340.9340.9340.9340.9340.93
Reserves92109125-92-24058108305369378388430444
Borrowings3063193531031009189504173677855
Other Liabilities -7162603593451231411328354616468
Trade Payables45.8736.5835.2429.9829.4829.8640.5044.5831.4120.6033.6837.2325.91
Other liability items24.6425.0325.09329.07315.7993.25100.2586.9251.9733.0627.7826.5542.14
Total Liabilities504526575407243310376527534546557612608
Fixed Assets -20527929418577736790979488103107
Gross Block252335360213123128130162184196202225
Accumulated Depreciation475666284655637287102114122
CWIP0000000000000
Investments368786824686868231234236236236
Other Assets -297180204154142170242369205217233273265
Inventories124988340405156514429427060
Trade receivables565167727491112125133155169178179
Cash Equivalents431333261803316833124
Loans n Advances751923146363927253121232
Other asset items-1-2-214-91-1-000120
Total Assets504526575407243310376527534546557612608

Cash Flows

Cash flow is the net amount of cash and cash-equivalents being transferred into and out of a business. At the most fundamental level, a company’s ability to create value for shareholders is determined by its ability to generate positive cash flows, or more specifically, maximize long-term free cash flow.

Standalone Figures in Rs. Crores

Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Cash from Operating Activity --258912-68-6195411265-141620
Profit from operations281418-106-634578114100243768
Receivables05-16-5-2-17-21-12-9-21-14-9
Inventory-0251543-0-11-45714-13-28
Payables2-9-2-3-192322-15-1024
Loans Advances-5356-455-16-14141000
Direct taxes-2-20-1-10-8-31-200-5-13
Other operating items00000-0000-219-2
Cash from Investing Activity --69-142-342641-48-2-29-177-8-8-20
Fixed assets purchased-75.16-83.62-25.140.00-4.56-4.91-2.61-32.23-22.20-11.78-5.86-23.45
Fixed assets sold0.000.000.0014.380.000.000.000.000.000.000.000.00
Investments purchased-0.01-64.86-10.060.0044.10-44.100.000.00-163.82-2.85-1.780.00
Investments sold0.000.000.0010.000.000.000.000.000.000.000.000.00
Interest received5.736.921.311.681.930.770.603.092.300.150.040.03
Dividends received0.000.000.000.000.000.000.000.006.386.690.003.62
Other investing items0.000.000.000.000.000.000.000.000.000.120.05-0.39
Cash from Financing Activity --202242361122-1951-5221-101
Proceeds from shares0.0017.120.000.000.004.480.00131.240.000.000.000.00
Proceeds from borrowings2.4914.6158.0648.960.000.000.000.000.000.000.000.00
Repayment of borrowings-18.10-1.52-24.230.00-15.02-228.580.000.000.000.000.000.00
Interest paid fin-4.71-8.11-8.32-13.43-9.45-7.40-6.82-6.22-2.76-4.49-7.67-6.56
Dividends paid0.000.000.000.000.000.00-5.61-6.97-6.96-5.91-2.46-2.05
Other financing items0.000.0016.270.0035.11253.99-6.78-66.77-42.1131.150.169.57
Net Cash Flow-115-3020-6-9-1733134-164-1-21

Ready to Invest?
Talk to our investment specialist
Disclaimer:
By submitting this form I authorize Fincash.com to call/SMS/email me about its products and I accept the terms of Privacy Policy and Terms & Conditions.

Ratios

Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
ROCE %7%4%3%-32%71%35%33%22%3%5%12%
Debtor Days8693123170175174130112136262209153
Inventory Turnover1.911.802.202.513.854.205.897.617.565.928.247.53

Announcements & News

Recent Announcements

How to Invest in Mutual Funds SIP Online?

  1. Open Free Investment Account for Lifetime at Fincash.com.
  2. Complete your Registration and KYC Process
  3. Upload Documents (PAN, Aadhaar, etc.). And, You are Ready to Invest! Get Started
  4. Invest in Mutual Funds which invests in Marksans Pharma Ltd & Get More Returns than Bank Deposit

Disclaimer:
All efforts have been made to ensure the information provided here is accurate as per time to time filling by company to exchanges. However, no guarantees are made regarding correctness of data. Investors are advised to validate/check information with exchanges or companies website before making any investment decisions.